G
Gottfried E. Konecny
Researcher at University of California, Los Angeles
Publications - 191
Citations - 14806
Gottfried E. Konecny is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 49, co-authored 168 publications receiving 12260 citations. Previous affiliations of Gottfried E. Konecny include Mayo Clinic & Ronald Reagan UCLA Medical Center.
Papers
More filters
Journal ArticleDOI
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz,Michael Untch,Jens-Uwe Blohmer,SD Costa,Holger Eidtmann,Peter A. Fasching,Bernd Gerber,Wolfgang Eiermann,Jörn Hilfrich,Jens Huober,Christian Jackisch,Manfred Kaufmann,Gottfried E. Konecny,Carsten Denkert,Valentina Nekljudova,Keyur Mehta,Sibylle Loibl +16 more
TL;DR: The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain this paper, however, it is known that pCR is associated with long-term outcome of 6,377 patients with primary breast cancer receiving neoadjuvant anthracycline-taxane-based chemotherapy in seven randomized trials.
Journal ArticleDOI
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert W Holloway,Margarita Amenedo Gancedo,Peter C.C. Fong,Jeffrey C. Goh,David M. O'Malley,Deborah K. Armstrong,Jesus Garcia-Donas,Elizabeth M. Swisher,Anne Floquet,Gottfried E. Konecny,Iain A. McNeish,Clare L. Scott,Terri Cameron,Lara Maloney,Jeff Isaacson,Sandra Goble,Caroline Grace,Thomas Harding,Mitch Raponi,James Sun,Kevin K. Lin,Heidi Giordano,Jonathan A. Ledermann,Martin Buck,A Dean,Michael Friedlander,J C Goh,Paul R. Harnett,G Kichenadasse,C L Scott,H Denys,Luc Dirix,Ignace Vergote,Laurie Elit,Prafull Ghatage,Amit M. Oza,Marie Plante,Diane Provencher,J I Weberpals,Stephen Welch,A Floquet,Laurence Gladieff,Florence Joly,A Leary,Alain Lortholary,Jean-Pierre Lotz,J. Medioni,Olivier Tredan,Benoit You,A El-Balat,C Hänle,P Krabisch,T Neunhöffer,M Pölcher,Pauline Wimberger,Amnon Amit,S Kovel,M Leviov,Tamar Safra,Ronnie Shapira-Frommer,Salomon M. Stemmer,Alessandra Bologna,N Colombo,Domenica Lorusso,Sandro Pignata,Roberto Sabbatini,G Scambia,Stefano Tamberi,Claudio Zamagni,P C Fong,A O'Donnell,M Amenedo Gancedo,A Casado Herraez,J Garcia-Donas,E M Guerra,A Oaknin,I Palacio,Iris L. Romero,A Sanchez,Susana Banerjee,A Clamp,Y Drew,Hani Gabra,D Jackson,Jonathan A. Ledermann,I A McNeish,Christine Parkinson,Melanie E Powell,C Aghajanian,D K Armstrong,Michael J. Birrer,Mary K. Buss,Setsuko K. Chambers,L-m Chen,Robert L. Coleman,R W Holloway,G E Konecny,L Ma,Mark A. Morgan,R T Morris,David G. Mutch,D M O'Malley,B M Slomovitz,E M Swisher,T Vanderkwaak,M Vulfovich +116 more
TL;DR: This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Journal ArticleDOI
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher,Kevin K. Lin,Amit M. Oza,Clare L. Scott,Heidi Giordano,James Sun,Gottfried E. Konecny,Robert L. Coleman,Anna V. Tinker,David M. O'Malley,Rebecca Kristeleit,Ling Ma,Katherine M. Bell-McGuinn,James D. Brenton,Janiel M. Cragun,Ana Oaknin,Isabelle Ray-Coquard,Maria I. Harrell,Elaina Mann,Scott H. Kaufmann,Anne Floquet,Alexandra Leary,Thomas Harding,Sandra Goble,Lara Maloney,Jeff Isaacson,Andrew R. Allen,Lindsey Rolfe,Roman Yelensky,Mitch Raponi,Iain A. McNeish +30 more
TL;DR: The ability of tumour genomic LOH, quantified with a next-generation sequencing assay, to predict response to rucaparib, an oral PARP inhibitor, was assessed in ARIEL2, an international, multicentre, two-part, phase 2, open-label study.
Journal ArticleDOI
Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
Gottfried E. Konecny,Mark D. Pegram,Natarajan Venkatesan,Richard S. Finn,Guorong Yang,Martina Rahmeh,Michael Untch,David W. Rusnak,Glenn M. Spehar,Robert J. Mullin,Barry R. Keith,Tona M. Gilmer,Mark S. Berger,Karl C. Podratz,Dennis J. Slamon +14 more
TL;DR: It is reported that concentration-dependent antiproliferative effects of lapatinib were seen in all breast cancer cell lines tested but varied significantly between individual cell lines with up to 1,000-fold difference in the IC(50)s (range, 0.010-18.6 micromol/L).
Journal ArticleDOI
Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer
Gottfried E. Konecny,Giovanni Pauletti,Murk Pegram,Michael Untch,Sugandha Dandekar,Zuleima Aguilar,Cindy A. Wilson,Hong-Mei Rong,Ingo Bauerfeind,Margret Felber,He-Jing Wang,Malgorzata Beryt,Rani Seshadri,H. Hepp,Dennis J. Slamon +14 more
TL;DR: Because absolute HR levels are strongly related to response to hormone therapy in primary and advanced breast cancer, reduced ER/PR expression may be one mechanism to explain the relative resistance of HER-2/neu-negative ones.